Moreover, while studies exploring the direct role of FGF21 in driving cardiac functional changes in NAFLD are limited, increased levels of circulating FGF21 have been observed in several cardiac diseases and have been associated with diastolic dysfunction in both humans and mice69–71. This evidence concerns the gene FGF21 and metabolic dysfunction-associated steatotic liver disease.